FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients

Central Council for Research in Ayurvedic Sciences launches ‘PRAGATI-2024’

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas

Ascentage releases results from multiple clinical studies of its lead drug candidates

These abstracts report on the company's three lead drug candidates, including olverembatinib

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset

Heuron gets FDA green light for stroke triage and notification solution

This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea

Ascentage Pharma releases latest results from multiple clinical studies of lead drug candidates

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models